Business
Moderna and Merck's Cancer Vaccine Success
Shares of Moderna and Merck have soared after the companies announced positive results from a late-stage trial of their personalized mRNA cancer vaccine.
Coverage timeline — 1 article
Axios
Moderna and Merck shares soared on Wednesday after the companies said a personalized mRNA treatment hit its target of preventing skin cancer from recurring or spreading in a late-st
2026-08-19 20:04 UTC